# A Pilot Study of Tumor-Specific Peptide Vaccination and IL-2 With or Without Autologous T Cell Transplantation in Recurrent Pediatric Sarcomas

> **NCT00001564** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 30 (actual)

## Conditions studied

- Ewing's Sarcoma
- Rhabdomyosarcoma

## Interventions

- **DRUG:** EF-1 Peptide
- **DRUG:** EF-2 Peptide
- **DRUG:** PXFK Peptide
- **DRUG:** E7 Peptide
- **DRUG:** IL-2
- **DRUG:** IL-4
- **DRUG:** GM-CSF
- **DRUG:** CD40 Ligand

## Key facts

- **NCT ID:** NCT00001564
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1996-12-23
- **Primary completion:** 2007-10-25
- **Final completion:** 2007-10-25
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2019-11-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00001564

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00001564, "A Pilot Study of Tumor-Specific Peptide Vaccination and IL-2 With or Without Autologous T Cell Transplantation in Recurrent Pediatric Sarcomas". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00001564. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*